Inbrija Capsule
Product Images NDC 0259-6142

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Inbrija (NDC 0259-6142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merz Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Inbrija 01)

FDA Label Image

Figure 1 (Inbrija 02)

This text shows data related to a study or experiment, with information about different groups and their measurements. The data includes values for the group named "Placebo" and another group named "WINBRWA 84 mg," as well as a time scale ranging from 20 to 60 minutes post-dose. The sample size of the groups is also provided for reference.*

FDA Label Image

Undefined (Inbrija 03)

This is a product description for a blue handle capsule with a white chamber mouthpiece. The text also mentions arrows and alignment, indicating that the product may have specific instructions or features related to these elements. The product is described as having a blue cap and may be part of a medical or dental device.*

FDA Label Image

Figure B (Inbrija 04)

FDA Label Image

Figure C (Inbrija 05)

This text provides information about Inbrija, which is a levodopa inhalation powder medication. It indicates that a full dose consists of two capsules, with each capsule containing 42mg. Additionally, the text mentions a specific address and references to lot numbers. Please consult the packaging or a medical professional for more details.*

FDA Label Image

Figure D (Inbrija 06)

FDA Label Image

Undefined (Inbrija 07)

FDA Label Image

Undefined (Inbrija 08)

This text appears to be a pharmaceutical label providing information about a medication including dosage amount per capsule and expiration date. The medication is manufactured by Merz Pharmaceuticals, located in Rockhil, North Carolina. The label contains a lot number and batch code. However, the specific name of the medication is not mentioned in the provided text.*

FDA Label Image

Undefined (Inbrija 09)

FDA Label Image

Undefined (Inbrija 10)

FDA Label Image

Undefined (Inbrija 11)

FDA Label Image

Undefined (Inbrija 12)

FDA Label Image

Undefined (Inbrija 13)

FDA Label Image

Undefined (Inbrija 14)

FDA Label Image

Undefined (Inbrija 15)

This text is readable and states "Release Mouthpiece". This could refer to a product or device used for protecting the mouth during sports or activities.*

FDA Label Image

Undefined (Inbrija 16)

FDA Label Image

Undefined (Inbrija 17)

This text is not readable.*

FDA Label Image

Undefined (Inbrija 18)

FDA Label Image

Undefined (Inbrija 19)

FDA Label Image

Undefined (Inbrija 20)

FDA Label Image

Undefined (Inbrija 21)

FDA Label Image

Undefined (Inbrija 22)

FDA Label Image

Figure U (Inbrija 23)

FDA Label Image

Figure V (Inbrija 23a)

FDA Label Image

Figure W (Inbrija 24)

FDA Label Image

Figure X (Inbrija 24a)

FDA Label Image

Figure Y (Inbrija 25)

FDA Label Image

Principal Display Panel (42 mg Capsule Blister Pack Carton)

This is a description of a medication called Inbrija, which is an inhalation powder containing levodopa. It is intended for oral inhalation only. Each Inbrija capsule contains 42 mg of levodopa along with inactive ingredients such as DPPC and sodium chloride. The medication should be stored between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Inbrija capsules should be stored in the blister and only removed right before use. Patients are advised to read the enclosed Patient Information and Instructions for Use before using the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.